Ibnsina Pharma (EGX:ISPH)

Ibnsina Pharma Balance Sheet

Financials in millions EGP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,396	835.86	1,131	541.21	468.54	270.88
Cash & Short-Term Investments	1,396	835.86	1,131	541.21	468.54	270.88
Cash Growth	15.37%	-26.08%	108.93%	15.51%	72.97%	128.66%
Accounts Receivable	18,789	16,267	9,761	5,775	5,743	3,267
Other Receivables	-	3.04	0.01	0.07	-	0.37
Receivables	18,789	16,270	9,761	5,775	5,743	4,831
Inventory	8,219	6,575	3,195	2,614	2,359	2,101
Prepaid Expenses	49.48	24.34	28.39	38.8	46.45	33.84
Other Current Assets	1,834	1,769	1,823	1,543	1,061	655.1
Total Current Assets	30,288	25,474	15,937	10,511	9,678	7,891
Property, Plant & Equipment	2,211	2,672	2,184	2,156	1,468	1,227
Long-Term Investments	-	-	15.92	-	-	-
Other Intangible Assets	226.31	218.37	219.02	30.18	15.3	6.9
Long-Term Deferred Tax Assets	300.51	228.73	114.4	82	59.39	11.58
Total Assets	33,062	28,642	18,550	12,864	11,284	9,250
Accounts Payable	6,234	5,833	3,661	1,593	1,399	917.38
Accrued Expenses	231.64	147.65	123.05	63.21	43.42	37.42
Short-Term Debt	8,119	4,379	3,165	2,290	1,568	607.9
Current Portion of Long-Term Debt	14,780	14,402	8,673	6,339	5,910	5,691
Current Portion of Leases	204.86	230.65	117.94	90.41	71.2	15.36
Current Income Taxes Payable	88.99	203.05	79.91	26.73	59.55	34.77
Current Unearned Revenue	49.3	38.16	17.96	16.77	15.32	-
Other Current Liabilities	203.9	193.44	85.74	50.93	335.18	149.79
Total Current Liabilities	29,912	25,427	15,924	10,470	9,401	7,454
Long-Term Debt	74.91	47.46	556.02	852.18	204.83	405.68
Long-Term Leases	692.76	1,136	620.42	281.67	224.8	26.27
Other Long-Term Liabilities	-	-	-	0	-	-
Total Liabilities	30,679	26,610	17,101	11,604	9,831	7,886
Common Stock	252	252	252	279.04	240	240
Additional Paid-In Capital	237.41	237.41	237.41	277.5	277.5	277.5
Retained Earnings	2,065	1,713	1,131	901.63	948.62	847.4
Treasury Stock	-171.64	-171.64	-171.64	-198.69	-14.4	-
Total Common Equity	2,383	2,031	1,449	1,259	1,452	1,365
Minority Interest	0	0	0	0.39	1.77	0
Shareholders' Equity	2,383	2,031	1,449	1,260	1,453	1,365
Total Liabilities & Equity	33,062	28,642	18,550	12,864	11,284	9,250
Total Debt	23,871	20,195	13,133	9,853	7,979	6,746
Net Cash (Debt)	-22,475	-19,359	-12,002	-9,312	-7,510	-6,475
Net Cash Per Share	-22.30	-19.21	-11.91	-9.24	-5.77	-5.78
Filing Date Shares Outstanding	1,008	1,008	1,008	1,008	1,226	1,120
Total Common Shares Outstanding	1,008	1,008	1,008	1,008	1,226	1,120
Working Capital	376.1	47.06	12.98	41.39	276.74	437.88
Book Value Per Share	2.36	2.02	1.44	1.25	1.18	1.22
Tangible Book Value	2,157	1,813	1,230	1,229	1,436	1,358
Tangible Book Value Per Share	2.14	1.80	1.22	1.22	1.17	1.21
Land	93.75	93.75	93.75	93.75	93.75	93.75
Buildings	862.83	847.39	807.75	724.3	692.7	654.85
Machinery	1,061	969.85	828.47	648.61	612.95	539.63
Construction In Progress	205.33	210.77	427.51	944.81	242.88	219.92

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.